Evidence map›Paper›PMID 31509593›Full record

ArticlePloS one2019

Epidemiology of pneumonia in the pre-pneumococcal conjugate vaccine era in children 2-59 months of age, in Ulaanbaatar, Mongolia, 2015-2016.

Claire von Mollendorf, Sophie La Vincente, Mukhchuluun Ulziibayar, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, John de Campo, Margaret de Campo, Cattram Nguyen, Sodbayar Demberelsuren and 2 more

Abstract readHistorical Article
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Claire von MollendorfNew Vaccines, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Vic., Australia.ORCID 0000-0003-0927-1731
Sophie La VincenteNew Vaccines, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Vic., Australia.
Mukhchuluun UlziibayarNational Center of Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
Bujinlkham SuuriNational Center of Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
Dashtseren LuvsantserenNational Center of Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
Dorj NarangerelMinistry of Health, Ulaanbaatar, Mongolia.
John de CampoNew Vaccines, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Vic., Australia.
Margaret de CampoNew Vaccines, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Vic., Australia.
Cattram NguyenNew Vaccines, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Vic., Australia.
Sodbayar DemberelsurenExpanded Programme on Immunization, World Health Organization, Ulaanbaatar, Mongolia.
Tuya MungunNational Center of Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
E Kim MulhollandNew Vaccines, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Vic., Australia.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundRespiratory diseases, including pneumonia, are the second largest cause of under-five mortality in Mongolia and the most common cause of childhood hospitalization. However information regarding the contribution of Streptococcus pneumoniae to pneumonia causation in Mongolia is limited. We aimed to describe the epidemiology of hospitalized children aged 2-59 months with pneumonia, enrolled into a surveillance program in the period prior to pneumococcal conjugate vaccine (PCV) introduction, in Mongolia.

methodsAn expanded pneumonia surveillance program enrolled children, who met the surveillance case definition, at participating hospitals, between April 2015 and May 2016. Cumulative incidence rates were calculated by district for all pneumonia endpoints using district specific denominators from the Mongolian Health Department census for 2016. Socio-economic and disease-associated factors were compared between districts using chi-squared tests.

resultsA total of 4318 eligible children with pneumonia were enrolled over the 14 month period. Overall the incidence for all-cause pneumonia in children aged 12-59 months was 31.8 per 1000 population; children aged 2-11 months had an almost four-fold higher incidence than children aged 12-59 months. Differences were found between districts with regards to housing type, fuel used for cooking, hospital admission practices and the proportions of severe and primary endpoint pneumonia. DISCUSSION: This study shows a high burden of pneumonia in children aged 2-59 months in Mongolia prior to PCV introduction. Rates differed somewhat by district and age group and were influenced by a number of socio-economic factors. It will be important to consider these differences and risk factors when assessing the impact of PCV introduction.

Indexed as

Child, HospitalizedChild, PreschoolFemaleHistory, 21st CenturyHospitalsHumansIncidenceInfantMaleMongoliaPneumococcal InfectionsPneumococcal VaccinesPneumoniaPneumonia, PneumococcalRisk FactorsStreptococcus pneumoniaePneumococcal VaccinesVaccines, Conjugate

Identifiers

PMID31509593
PMCPMC6738602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.